Shopping Cart 0
Cart Subtotal
USD 0

BioCryst Pharmaceuticals Inc (BCRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. Biocryst integrates disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The company's products include peramivir injections, which consists of Rapivab, Alpivab, Rapiacta and Peramiflu for the treatment of Influenza. The company has strategic partnerships with corporate and academic institutes. BioCryst has research operations in Birmingham, Alabama and is headquartered in Durham, North Carolina, the US.

BioCryst Pharmaceuticals Inc (BCRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

BioCryst Pharma Enters into Licensing Agreement with Seqirus 11

Equity Offering 13

BioCryst Pharma Rises USD57.5 Million in Public Offering of Shares 13

BioCryst Pharma Raises USD92 Million in Public Offering of Shares 15

BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 17

BioCryst Pharma Prices Public Offering of Shares for USD45 Million 18

BioCryst Pharma Raises USD115 Million in Public Offering of Shares 20

BioCryst Pharma Completes Public Offering Of Shares For USD 20.3 Million 22

BioCryst Pharmaceuticals Inc-Key Competitors 24

BioCryst Pharmaceuticals Inc-Key Employees 25

BioCryst Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Nov 06, 2018: BioCryst reports third quarter 2018 financial results 27

Aug 07, 2018: BioCryst Reports Second Quarter 2018 Financial Results 29

May 08, 2018: BioCryst Reports First Quarter 2018 Financial Results 31

Feb 27, 2018: BioCryst Announces Fourth Quarter and Full Year 2017 Financial Results 33

Nov 07, 2017: BioCryst Reports Third Quarter 2017 Financial Results 35

Aug 07, 2017: BioCryst Reports Second Quarter 2017 Financial Results 37

May 04, 2017: BioCryst Reports First Quarter 2017 Financial Results 39

Feb 27, 2017: BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results 41

Corporate Communications 43

May 30, 2017: Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals 43

Legal and Regulatory 44

Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 44

Product News 45

10/04/2017: BioCryst Announces RAPIVAB (peramivir injection) Presentations at IDWeek 2017 45

09/21/2017: BioCrysts RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication 46

06/05/2017: BioCryst Announces RAPIVAB Pediatric sNDA Acceptance 47

05/24/2018: BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema 48

02/23/2018: The European Medicines Agency's CHMP Recommends Marketing Authorisation for Alpivab 49

Product Approvals 50

Jan 30, 2017: BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency 50

Jan 08, 2017: BioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza 51

Clinical Trials 52

May 29, 2018: BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress 52

Mar 15, 2018: BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema 53

Feb 28, 2018: BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema 54

Jan 05, 2018: BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva 55

Oct 27, 2017: BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI's 2017 Annual Scientific Meeting 56

Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE 57

Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks 59

May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial 60

Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks 61

Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial 62

Other Significant Developments 64

Jun 05, 2018: BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera 64

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioCryst Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BioCryst Pharma Enters into Licensing Agreement with Seqirus 11

BioCryst Pharma Rises USD57.5 Million in Public Offering of Shares 13

BioCryst Pharma Raises USD92 Million in Public Offering of Shares 15

BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 17

BioCryst Pharma Prices Public Offering of Shares for USD45 Million 18

BioCryst Pharma Raises USD115 Million in Public Offering of Shares 20

BioCryst Pharma Completes Public Offering Of Shares For USD 20.3 Million 22

BioCryst Pharmaceuticals Inc, Key Competitors 24

BioCryst Pharmaceuticals Inc, Key Employees 25

BioCryst Pharmaceuticals Inc, Other Locations 26

BioCryst Pharmaceuticals Inc, Subsidiaries 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

BioCryst Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

BioCryst Pharmaceuticals Inc (BioCryst) designs, optimizes and develops small molecule drugs that block key enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary Angioedemaon. Biocryst integrates disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The company's products include peramivir injections, which consists of Rapivab, Alpivab, Rapiacta and Peramiflu for the treatment of Influenza. The company has strategic partnerships with corporate and academic institutes. BioCryst has research operations in Birmingham, Alabama and is headquartered in Durham, North Carolina, the US.

BioCryst Pharmaceuticals Inc (BCRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

BioCryst Pharma Enters into Licensing Agreement with Seqirus 11

Equity Offering 13

BioCryst Pharma Rises USD57.5 Million in Public Offering of Shares 13

BioCryst Pharma Raises USD92 Million in Public Offering of Shares 15

BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 17

BioCryst Pharma Prices Public Offering of Shares for USD45 Million 18

BioCryst Pharma Raises USD115 Million in Public Offering of Shares 20

BioCryst Pharma Completes Public Offering Of Shares For USD 20.3 Million 22

BioCryst Pharmaceuticals Inc-Key Competitors 24

BioCryst Pharmaceuticals Inc-Key Employees 25

BioCryst Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Nov 06, 2018: BioCryst reports third quarter 2018 financial results 27

Aug 07, 2018: BioCryst Reports Second Quarter 2018 Financial Results 29

May 08, 2018: BioCryst Reports First Quarter 2018 Financial Results 31

Feb 27, 2018: BioCryst Announces Fourth Quarter and Full Year 2017 Financial Results 33

Nov 07, 2017: BioCryst Reports Third Quarter 2017 Financial Results 35

Aug 07, 2017: BioCryst Reports Second Quarter 2017 Financial Results 37

May 04, 2017: BioCryst Reports First Quarter 2017 Financial Results 39

Feb 27, 2017: BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results 41

Corporate Communications 43

May 30, 2017: Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals 43

Legal and Regulatory 44

Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 44

Product News 45

10/04/2017: BioCryst Announces RAPIVAB (peramivir injection) Presentations at IDWeek 2017 45

09/21/2017: BioCrysts RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication 46

06/05/2017: BioCryst Announces RAPIVAB Pediatric sNDA Acceptance 47

05/24/2018: BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema 48

02/23/2018: The European Medicines Agency's CHMP Recommends Marketing Authorisation for Alpivab 49

Product Approvals 50

Jan 30, 2017: BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency 50

Jan 08, 2017: BioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza 51

Clinical Trials 52

May 29, 2018: BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress 52

Mar 15, 2018: BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema 53

Feb 28, 2018: BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema 54

Jan 05, 2018: BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva 55

Oct 27, 2017: BioCryst Announces Late Breaker Presentation of BCX7353 Phase 2 APeX-1 Trial Results at the ACAAI's 2017 Annual Scientific Meeting 56

Sep 05, 2017: BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE 57

Aug 02, 2017: BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks 59

May 25, 2017: BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial 60

Apr 12, 2017: BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks 61

Feb 27, 2017: BioCryst Reports Positive Interim Results from its APeX-1 Trial 62

Other Significant Developments 64

Jun 05, 2018: BioCryst Issues Letter to Stockholders Reiterating Upside Potential of Value-Enhancing Merger with Idera 64

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BioCryst Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

BioCryst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BioCryst Pharma Enters into Licensing Agreement with Seqirus 11

BioCryst Pharma Rises USD57.5 Million in Public Offering of Shares 13

BioCryst Pharma Raises USD92 Million in Public Offering of Shares 15

BioCryst Pharma Files Registration Statement to Raise Funds through Public Offering of Shares 17

BioCryst Pharma Prices Public Offering of Shares for USD45 Million 18

BioCryst Pharma Raises USD115 Million in Public Offering of Shares 20

BioCryst Pharma Completes Public Offering Of Shares For USD 20.3 Million 22

BioCryst Pharmaceuticals Inc, Key Competitors 24

BioCryst Pharmaceuticals Inc, Key Employees 25

BioCryst Pharmaceuticals Inc, Other Locations 26

BioCryst Pharmaceuticals Inc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

BioCryst Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.